Literature DB >> 8807587

Renal nitric oxide synthases in transgenic sickle cell mice.

N Bank1, H S Aynedjian, J H Qiu, S Y Osei, R S Ahima, M E Fabry, R L Nagel.   

Abstract

The alpha H beta S [beta MDD] mouse is a useful model for studying renal functional abnormalities in sickle cell disease. We previously reported that these mice develop a urine concentrating defect when chronically exposed to a low oxygen environment. In the present study, we measured glomerular filtration rate (GFR), urinary excretion of NO2 s+ NO3, the stable products of nitric oxide (NO), and the abundance of endothelial constitutive nitric oxide synthase (NOS III) and inducible nitric oxide synthase (NOS II) in the kidneys by Western blot. Immunohistochemistry was also carried out. We found that GFR is significantly higher in the transgenic mice than in controls. The urinary NO2 + NO3/creatinine ratio was also higher. The Western blots revealed that both NOS III and NOS II are markedly increased in the kidneys of transgenic mice as compared to normal control mice. Immunohistochemistry localized NOS III reactivity in proximal convoluted cells in the cortex of control and alpha H beta S [beta MDD] mice. NOS II immunostaining was not seen in control mice but was clearly evident in glomeruli and distal nephron segments of the alpha H beta S [beta MDD] mice. These observations suggest that NOS II is induced in glomeruli and distal nephrons of the alpha H beta S [beta MDD] mice. An increase in synthesis of NO may occur in the glomeruli as a result of NOS II induction, and this may contribute to the hyperfiltration in these mice.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8807587     DOI: 10.1038/ki.1996.301

Source DB:  PubMed          Journal:  Kidney Int        ISSN: 0085-2538            Impact factor:   10.612


  20 in total

Review 1.  Sickle cell disease: renal manifestations and mechanisms.

Authors:  Karl A Nath; Robert P Hebbel
Journal:  Nat Rev Nephrol       Date:  2015-02-10       Impact factor: 28.314

2.  Dysregulated arginine metabolism, hemolysis-associated pulmonary hypertension, and mortality in sickle cell disease.

Authors:  Claudia R Morris; Gregory J Kato; Mirjana Poljakovic; Xunde Wang; William C Blackwelder; Vandana Sachdev; Stanley L Hazen; Elliott P Vichinsky; Sidney M Morris; Mark T Gladwin
Journal:  JAMA       Date:  2005-07-06       Impact factor: 56.272

3.  Oxidative stress and induction of heme oxygenase-1 in the kidney in sickle cell disease.

Authors:  K A Nath; J P Grande; J J Haggard; A J Croatt; Z S Katusic; A Solovey; R P Hebbel
Journal:  Am J Pathol       Date:  2001-03       Impact factor: 4.307

Review 4.  Sickle cell nephropathy: challenging the conventional wisdom.

Authors:  Amy M Becker
Journal:  Pediatr Nephrol       Date:  2011-01-04       Impact factor: 3.714

5.  Transient receptor potential vanilloid 1 mediates pain in mice with severe sickle cell disease.

Authors:  Cheryl A Hillery; Patrick C Kerstein; Daniel Vilceanu; Marie E Barabas; Dawn Retherford; Amanda M Brandow; Nancy J Wandersee; Cheryl L Stucky
Journal:  Blood       Date:  2011-06-27       Impact factor: 22.113

6.  Synthetic oligosaccharides can replace animal-sourced low-molecular weight heparins.

Authors:  Yongmei Xu; Kasemsiri Chandarajoti; Xing Zhang; Vijayakanth Pagadala; Wenfang Dou; Debra Moorman Hoppensteadt; Erica M Sparkenbaugh; Brian Cooley; Sharon Daily; Nigel S Key; Diana Severynse-Stevens; Jawed Fareed; Robert J Linhardt; Rafal Pawlinski; Jian Liu
Journal:  Sci Transl Med       Date:  2017-09-06       Impact factor: 17.956

Review 7.  Renal complications of sickle cell disease: managing for optimal outcomes.

Authors:  Luciana de Santis Feltran; João Thomás de Abreu Carvalhaes; Ricardo Sesso
Journal:  Paediatr Drugs       Date:  2002       Impact factor: 3.022

8.  Hydroxyurea treatment decreases glomerular hyperfiltration in children with sickle cell anemia.

Authors:  Banu Aygun; Nicole A Mortier; Matthew P Smeltzer; Barry L Shulkin; Jane S Hankins; Russell E Ware
Journal:  Am J Hematol       Date:  2012-12-17       Impact factor: 10.047

Review 9.  Beyond the definitions of the phenotypic complications of sickle cell disease: an update on management.

Authors:  Samir K Ballas; Muge R Kesen; Morton F Goldberg; Gerard A Lutty; Carlton Dampier; Ifeyinwa Osunkwo; Winfred C Wang; Carolyn Hoppe; Ward Hagar; Deepika S Darbari; Punam Malik
Journal:  ScientificWorldJournal       Date:  2012-08-01

10.  Novel marker for the detection of sickle cell nephropathy: soluble FMS-like tyrosine kinase-1 (sFLT-1).

Authors:  Ilham Youssry; Samuel Makar; Rania Fawzy; Manal Wilson; Ghada AbdAllah; Eman Fathy; Happy Sawires
Journal:  Pediatr Nephrol       Date:  2015-08-04       Impact factor: 3.714

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.